HealthEdge Investment Fund II has acquired a majority interest in LifeSync Corporation, its first portfolio company. Headquartered in Ft. Lauderdale, Florida and founded in 2000, LifeSync is a manufacturer and distributor of patent-protected, disposable, wireless, radiolucent ECG devices that have applications in hospitals and other surgical facilities.
HealthEdge Investment Fund II, L.P. (“Fund II”) announced today that it has acquired a majority interest in LifeSync Corporation (“LifeSync”), its first portfolio company in Fund II.
Headquartered in Ft. Lauderdale, Florida and founded in 2000, LifeSync is a manufacturer and distributor of patent-protected, disposable, wireless, radiolucent ECG (or EKG) devices that have applications in numerous and diverse departments in hospitals and other surgical facilities. The product is designed to lower hospital costs due primarily to increased nurse productivity and patient mobility, improve the quality of vital signs and data transmission, reduce false alarms, enhance imaging results, and reduce the rate of infection at hospitals. The company has an excellent blue chip customer list, and the product is currently sold in the U.S. market through direct sales representatives.
In connection with the transaction, LifeSync has appointed Kim Davis as its Chief Executive Officer. Mr. Davis is a 25 year+ seasoned executive with a track record of improving shareholder value by making companies more efficient, productive, profitable, and global. Mr. Davis was most recently the Chairman, CEO, and President of SmartFlow Technologies, a company in the crossflow filtration space, where he held responsibility for all aspects of worldwide operations including sales, marketing, research and development, manufacturing, and finance. Mr. Davis successfully revived a near failed business (and investment) on behalf of a private equity fund culminating in a positive exit to a strategic buyer. Prior to that effort, Mr. Davis was the President and CEO of Porex Corporation, a subsidiary of WebMD Corporation, where he grew annual sales from $56 million to $122 million through organic growth, international expansion, and acquisition. Mr. Davis has also served as President and CEO of Gelman Sciences Inc., a manufacturer of life science disposables, FDA approved medical devices, and process filtration, where he grew annual sales from $81 million to $125 million and sold the business to Pall Corporation, and COO of Promega Corporation (a Baird Capital Partners portfolio company), a developer of molecular biology reagents, DNA and protein purification kits, fluorescent tags, and cellular regulation kits supplied to the pharma and biotech markets.